Φορτώνει......
Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
Alemtuzumab, an anti-CD52 monoclonal antibody, is effective in the treatment of relapsing–remitting multiple sclerosis (RRMS). Common adverse effects include the development of autoimmune diseases, and Graves’ disease is one of the most frequent presentations. We report here a case of alemtuzumab-in...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Int J Immunopathol Pharmacol |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
SAGE Publications
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6458661/ https://ncbi.nlm.nih.gov/pubmed/30968726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2058738419843690 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|